Combos May Extend Reach of CDK4/6 Inhibitors in Breast Cancer

Published: Monday, Jan 29, 2018
Charles J. Sherr, MD, PhD
Charles J. Sherr, MD, PhD
Many therapies for patients with breast cancer focus on targeting cancer cell proliferation, with a goal of diverting cells to a more senescent phenotype. In recent years, oncology drug developers have been able to leverage knowledge about a cause of proliferation— dysregulated activity of the cyclin-dependent kinases (CDKs)—to create a new class of therapy that has rapidly been integrated into the breast cancer treatment paradigm.


Figure. Role of CDK4 and 6 in the Cell Cycle1

Role of CDK4 and 6
Palbociclib, the first agent in this class to gain the FDA’s approval, is indicated for the treatment of women with hormone receptor (HR)– positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) as initial endocrine therapy in postmenopausal women as well as in combination with fulvestrant (Faslodex) following progression on endocrine therapy.

Ongoing Research in Breast Cancer Subtypes

Brain Metastasis
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication